I-Clenbuterol, i-agonist ye-β2-adrenergic (i-β2-adrenergic agonist), efana ne-ephedrine (Ephedrine), isoloko isetyenziselwa ukunyanga izifo ezingapheliyo ze-pulmonary (COPD), Ikwasetyenziswa njenge-bronchodilator ukukhulula ukunyanzeliswa kwe-asthma exacerbations.Ekuqaleni kweminyaka yoo-1980, inkampani yaseMelika iCyanamid ngempazamo yafumanisa ukuba ineziphumo ezicacileyo zokukhuthaza ukukhula, ukuphucula izinga lenyama ebhityileyo kunye nokunciphisa amanqatha, ngoko yayisetyenziswa njenge-clenbuterol ekufuyweni kwezilwanyana.Nangona kunjalo, ngenxa yeziphumo ebezingalindelekanga, uMbutho waseYurophu wavala ukusetyenziswa clenbuterol njengoko isondlo sokongeza ukususela ngoJanuwari 1, 1988. Yavalwa FDA ngo 1991. Ngo-1997, iSebe lezoLimo kwiRiphabhlikhi yaBantu baseChina yalela ngokungqongqo. ukusetyenziswa kwehomoni ze-beta-adrenergic kwisondlo kunye nemveliso yezilwanyana, kunye neClenbuterol hydrochloride kwindawo yokuqala.
Nangona kunjalo, iClenbuterol yobuhlanga isanda kuboniswa ukunciphisa umngcipheko wesifo sikaParkinson.Ukuqinisekisa ukuba yeyiphi (okanye zombini) i-isomers evelisa le mpembelelo, i-enantiomer ecocekileyo ye-Clenbuterol kufuneka ifundwe ngokwahlukileyo.
Kwinqaku lakutshanje, iqela lophando lika-Elisabeth Egholm Jacobsen weSebe leKhemistry, iYunivesithi yaseNorway yeSayensi kunye neTekhnoloji, ngokubambisana noDkt Zhu Wei waseShangke Bio, i-catalyzed synthesis ye-ketoreductase KRED kunye ne-cofactor nicotinamide adenine dinucleoside phosphate (NADPH) ).(R) -1- (4-Amino-3,5-dichlorophenyl) -2-bromoethan-1-ol, ee> 93%;kunye (S)-N-(2 yaxutywa yinkqubo efanayo ,6-Dichloro-4-(1-hydroxyethyl)phenyl)acetamide, ee>98%.Zombini ezi ziphakathi zingentla zinokuba ngabaphambili be-clenbuterol isomers.I-ketoreductase ES-KRED-228 esetyenziswe kolu cwaningo yayivela e-Shangke Biopharmaceutical (Shanghai) Co., Ltd. Isiphumo sophando "I-Chemoenzymatic Synthesis ye-Synthons njenge-Precursors ye-Enantiopure Clenbuterol kunye nezinye -2-Agonists" yapapashwa kwi "Catalysts" kwi. NgoNovemba 4, 2018.
Ixesha lokuposa: Aug-26-2022